blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2773337

EP2773337 - USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  26.07.2019
Database last updated on 07.04.2026
FormerThe patent has been granted
Status updated on  17.08.2018
FormerGrant of patent is intended
Status updated on  23.07.2018
FormerExamination is in progress
Status updated on  05.05.2017
Most recent event   Tooltip03.07.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 05.08.2020  [2020/32]
Applicant(s)For all designated states
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
Bâtiment le Ponant D
25 rue Leblanc
75015 Paris / FR
[2014/37]
Inventor(s)01 / MOUTHON, Franck
10 place Corneille
F-92100 Boulogne Billancourt / FR
02 / CHARVERIAT, Mathieu
41 rue Foucher Lepelletier
F-92130 Issy Les Moulineaux / FR
 [2014/37]
Representative(s)Regimbeau
20, rue de Chazelles
75847 Paris Cedex 17 / FR
[2014/37]
Application number, filing date12778762.031.10.2012
[2018/38]
WO2012EP71631
Priority number, dateEP2011030640731.10.2011         Original published format: EP 11306407
[2014/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013064579
Date:10.05.2013
Language:EN
[2013/19]
Type: A1 Application with search report 
No.:EP2773337
Date:10.09.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 10.05.2013 takes the place of the publication of the European patent application.
[2014/37]
Type: B1 Patent specification 
No.:EP2773337
Date:19.09.2018
Language:EN
[2018/38]
Search report(s)International search report - published on:EP10.05.2013
ClassificationIPC:A61K31/19, A61K31/445, A61P25/28, A61K31/196, A61K45/06
[2018/31]
CPC:
A61K31/445 (EP,IL,US); A61K31/19 (EP,IL,US); A61K31/196 (EP,IL,US);
A61K31/49 (IL,US); A61K45/06 (EP,IL,US); A61P25/28 (EP,IL,US)
C-Set:
A61K31/19, A61K2300/00 (EP,US);
A61K31/445, A61K2300/00 (US,EP)
Former IPC [2014/37]A61K31/19, A61K31/445, A61P25/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/37]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERWENDUNG VON ANTI-CONNEXIN-WIRKSTOFFEN ZUR VERBESSERUNG DES THERAPEUTISCHEN EFFEKTS EINES ACETYLCHOLINESTERASEHEMMERS[2018/31]
English:USE OF ANTI-CONNEXIN AGENTS FOR ENHANCING THE THERAPEUTIC EFFECT OF ACETYLCHOLINESTERASE INHIBITORS[2014/37]
French:UTILISATION D'AGENTS ANTI-CONNEXINE POUR AMÉLIORER L'EFFET THÉRAPEUTIQUE D'UN INHIBITEUR DE L'ACÉTYLCHOLINESTÉRASE[2018/31]
Former [2014/37]VERWENDUNG VON ANTI-CONNEXIN-WIRKSTOFFEN ZUR VERBESSERUNG DER THERAPEUTISCHEN WIRKUNG VON ACETYLCHOLINESTERASEHEMMERN
Former [2014/37]UTILISATION D'AGENTS ANTI-CONNEXINE POUR AMÉLIORER L'EFFET THÉRAPEUTIQUE DES INHIBITEURS DE L'ACÉTYLCHOLINESTÉRASE
Entry into regional phase26.05.2014National basic fee paid 
26.05.2014Designation fee(s) paid 
26.05.2014Examination fee paid 
Examination procedure26.05.2014Examination requested  [2014/37]
23.01.2015Amendment by applicant (claims and/or description)
04.05.2017Despatch of a communication from the examining division (Time limit: M06)
25.09.2017Reply to a communication from the examining division
27.02.2018Despatch of a communication from the examining division (Time limit: M02)
20.03.2018Reply to a communication from the examining division
24.07.2018Communication of intention to grant the patent
10.08.2018Fee for grant paid
10.08.2018Fee for publishing/printing paid
10.08.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18195298.7  / EP3446688
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.05.2017
Opposition(s)20.06.2019No opposition filed within time limit [2019/35]
Fees paidRenewal fee
08.10.2014Renewal fee patent year 03
07.10.2015Renewal fee patent year 04
06.10.2016Renewal fee patent year 05
27.10.2017Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL19.09.2018
CY19.09.2018
LT19.09.2018
LV19.09.2018
MC19.09.2018
MK19.09.2018
RS19.09.2018
SI19.09.2018
SM19.09.2018
MT31.10.2018
BG19.12.2018
GR20.12.2018
[2020/31]
Former [2020/08]AL19.09.2018
LT19.09.2018
LV19.09.2018
MC19.09.2018
RS19.09.2018
SI19.09.2018
SM19.09.2018
MT31.10.2018
BG19.12.2018
GR20.12.2018
Former [2019/50]AL19.09.2018
LT19.09.2018
LV19.09.2018
MC19.09.2018
RS19.09.2018
SI19.09.2018
SM19.09.2018
BG19.12.2018
GR20.12.2018
Former [2019/33]AL19.09.2018
LT19.09.2018
LV19.09.2018
MC19.09.2018
RS19.09.2018
SM19.09.2018
BG19.12.2018
GR20.12.2018
Former [2019/27]AL19.09.2018
LT19.09.2018
LV19.09.2018
RS19.09.2018
SM19.09.2018
BG19.12.2018
GR20.12.2018
Former [2019/13]AL19.09.2018
LT19.09.2018
LV19.09.2018
RS19.09.2018
BG19.12.2018
GR20.12.2018
Former [2019/11]LT19.09.2018
RS19.09.2018
BG19.12.2018
GR20.12.2018
Former [2019/07]LT19.09.2018
Cited inInternational search[Y]   MCGLEENON ET AL: "Acetylcholinesterase inhibitors in Alzheimer's disease", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 48, no. 4, 1 October 1999 (1999-10-01), pages 471 - 480, XP055022038, ISSN: 0306-5251, DOI: 10.1046/j.1365-2125.1999.00026.x

DOI:   http://dx.doi.org/10.1046/j.1365-2125.1999.00026.x
 [Y]   GASPARINI LAURA ET AL: "Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action", JOURNAL OF NEUROCHEMISTRY, vol. 91, no. 3, November 2004 (2004-11-01), pages 521 - 536, XP002671653, ISSN: 0022-3042

DOI:   http://dx.doi.org/10.1111/J.1471-4159.2004.02743.X
Examination  JUSZCZAK G R ET AL: "Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: Animal and human studies", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, ELSEVIER, GB, vol. 33, no. 2, 17 March 2009 (2009-03-17), pages 181 - 198, XP025952919, ISSN: 0278-5846, [retrieved on 20090101], DOI: 10.1016/J.PNPBP.2008.12.014

DOI:   http://dx.doi.org/10.1016/j.pnpbp.2008.12.014
by applicant  HARKS EG, THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 8, no. 3, 29 September 2001 (2001-09-29), pages 1033 - 41
   PAN F, VIS NEUROSCIENCES, vol. 24, no. 4, July 2007 (2007-07-01), pages 609 - 18
   SRINIVAS M, PNAS, vol. 98, 2001, pages 10942 - 10947
   PAN F, V, NEUROSCIENCES, vol. 24, no. 4, July 2007 (2007-07-01), pages 609 - 18
   BURT JM ET AL., CIRC RESEARCH., vol. 65, 1989, pages 829 - 37
   GUAN X. ET AL., J. CELL BIOL, vol. 139, 1997, pages 1785 - 92
   LOCKE D. ET AL., J. BIOL CHEM, vol. 279, 2004, pages 22883 - 92
   BAI D, J PHARMACOL EXP THEY, vol. 319, no. 3, December 2006 (2006-12-01), pages 1452 - 8
   BAI D, J PHARMACOL EXP THER, vol. 319, no. 3, December 2006 (2006-12-01), pages 1452 - 8
   HOFER A ET AL., GLIA, vol. 24, 1998, pages 141 - 54
   MEYER RA, J. CELL BIOL., vol. 119, 1992, pages 179 - 89
   DAHL G. ET AL., BIOPHYS J, vol. 67, 1994, pages 1816 - 22
   CHAYTOR A T ET AL., J. PHYSIOL, vol. 503, 1997, pages 99 - 110
   SCEMES E, GLIA, vol. 56, no. 2, 15 January 2008 (2008-01-15), pages 145 - 53
   POSTMA FR, J CELL BIOI, vol. 140, no. 5, 9 March 1998 (1998-03-09), pages 1199 - 209
   SHAW RM, CE11, vol. 128, no. 3, 9 February 2007 (2007-02-09), pages 547 - 60
   FABRIZI GM, BRAIN, vol. 130, February 2007 (2007-02-01), pages 394 - 403
   SRIVINAS M; CONNEXINS: "A Guide", 2009, HUMANA PRESS, pages: 207 - 224
   SRINIVAS M, MOLECULAR PHARMACOLOGY, vol. 3, no. 6, 6 June 2003 (2003-06-06), pages 1389 - 97
   HARKS EG, THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL HERAPEUTICS, vol. 8, no. 3, 29 September 2001 (2001-09-29), pages 1033 - 41
   SALAMEH A, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1719, 2005, pages 36 - 58
   DHEIN S., CARDIOVASCULAR RESEARCH, 2004, pages 287 - 298
   YAO J; MORIOKA T; OITE T., KIDNRY INT., vol. 57, 2000, pages 1915 - 26
   YAO J; HIRAMATSU N; ZHU Y ET AL., JAM SOC NEPHROL., vol. 16, 2005, pages 58 - 67
   FIGUEROA XF; ALVINA K; MARTINEZ AD ET AL., MICROVASC RES., vol. 68, 2004, pages 247 - 57
   ALLDREDGE BT., J CLIN PATHOL., 12 May 2008 (2008-05-12)
   LAI-CHEONG JE; ARITA K; MCGRATH JA., J INVESTDERMATOL., vol. 127, 2007, pages 2713 - 25
   GIEPMANS BN., CARDIOVASC RES., vol. 62, 2004, pages 233 - 45
   BERGMAN ET AL., NEUROPHARMACOL, vol. 25, no. 2, 2002, pages 107 - 110
   BIRKS J., COCHRANE DATABASE 3JST REV., 2006, pages CD001190
   JOHANSSEN P. ET AL., CNS DRUGS, vol. 20, no. 4, 2006, pages 311 - 25
   GAUTHIER S. ET AL., CURT. MED. RES. OPINION, vol. 18, no. 6, 2002, pages 347 - 54
   NIEOULLON A., PSYCHOL. NEUROPSYCHIATR. VIEIL., vol. 8, no. 2, 2010, pages 123 - 31
   WAGNER C. ET AL., AM. J. PHYSIOL. REGUL INTEGR. COMP. PHYSIOL., vol. 293, 2007, pages R1781 - 6
   BONTEMPI B. ET AL., NEUROPSYCHOPHARMACOLOGY, vol. 28, 2003, pages 1235 - 46
   JOO Y. ET AL., MOLECULAR PHARMACOLOGY, vol. 69, 2006, pages 76 - 84
   BERACOCHEA D.J.; JAFFARD R., BEHAV. NEUROSCI., vol. 101, 1987, pages 187 - 97
   GALDERISI S. ET AL., METHODS FIND. EXP. CLIN. PHARMACOL., vol. 24, 2002, pages 79
   TRONCHE C. ET AL., BEHAV. BRAIN. RES., vol. 215, 2010, pages 255 - 260
   SPOWART-MANNING L., BEHAV. BRAIN. RES., vol. 151, 2004, pages 37 - 46
   BONTEMPI B. ET AL., NEUROPSYCHOPHARMACOLOGY, vol. 28, 2003, pages 1235 - 12460
   WALTHER T. ET AL., PLO3' ONE, 2009, pages E4590
   BERACOCHEA D. ET AL., PSYCHOPHARMACOLOGY (BERL, vol. 193, 2007, pages 63 - 73
   GLEENON ET AL., BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 48, 1999, pages 471 - 480
   GASPARINI L. ET AL., JOURNAL OF NEUROCHEMISTRY, vol. 91, 2004, pages 521 - 536
   HANSEEUW B.J. ET AL., BRAIN COGN., vol. 72, pages 325 - 31
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.